Author Title [ Type(Desc)] Year
Filters: Author is Forman, Stephen J  [Clear All Filters]
Journal Article
Wang Z, McWilliams-Koeppen HP, Reza H, Ostberg JR, Chen W, Wang X, Huynh C, Vyas V, Chang W-C, Starr R, et al. 3D-organoid culture supports differentiation of human CAR iPSCs into highly functional CAR T cells. Cell Stem Cell. 2022.
Wang Z, McWilliams-Koeppen HP, Reza H, Ostberg JR, Chen W, Wang X, Huynh C, Vyas V, Chang W-C, Starr R, et al. 3D-organoid culture supports differentiation of human CAR iPSCs into highly functional CAR T cells. Cell Stem Cell. 2022;29(4):651-653.
Herrera AF, Chen L, Khajavian S, Chase M, Darrah J, Maloney D, Ho VT, Soiffer RJ, Antin JH, Forman SJ, et al. Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B-cell Lymphoma. Biol Blood Marrow Transplant. 2019.
Slavin TP, Teh JBerano, Weitzel JN, Peng K, F Wong L, Qin H, Wang J, Wu X, Mei M, Pillai R, et al. Association between Clonal Hematopoiesis and Late Non-Relapse Mortality after Autologous Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019.
Stevens BM, Zhang W, Pollyea DA, Winters A, Gutman J, Smith C, Budde E, Forman SJ, Jordan CT, Purev E. CD123 CAR T Cells for the Treatment of Myelodysplastic Syndrome. Exp Hematol. 2019.
Kambhampati S, Saumoy M, Schneider Y, Serrao S, Solaimani P, Budde LElizabeth, Mei MG, Popplewell L, Siddiqi T, Zain J, et al. Cost Effectiveness of Second-Line Axicabtagene ciloleucel in Relapsed Refractory Diffuse Large B-cell Lymphoma. Blood. 2022.
Otoukesh S, Elmariah H, Yang D, Clark MC, Siraj M, Ali H, Mogili K, Arslan S, Nishihori T, Nakamura R, et al. Cytokine Release Syndrome Following Peripheral Blood Stem Cell Haploidentical HCT with Post-Transplant Cyclophosphamide: CRS post haploidentical HCT with PTCy. Transplant Cell Ther. 2021.
Nakamura R, Gendzekhadze K, Palmer J, Tsai N-C, Mokhtari S, Forman SJ, Zaia JA, Senitzer D, Marcucci G, Stein A. Influence of donor KIR genotypes on reduced relapse risk in acute myelogenous leukemia after hematopoietic stem cell transplantation in patients with CMV reactivation. Leuk Res. 2019;87:106230.
Gangaraju R, Chen Y, Hageman L, Wu J, Francisco L, Kung M, Weisdorf DJ, Forman SJ, Arora M, Armenian S, et al. Late-occurring Venous Thromboembolism in Allogeneic Blood or Marrow Transplant Survivors - a BMTSS-HiGHS2 Risk Model. Blood Adv. 2021.
Malki MMAl, Gendzekhadze K, Yang D, Mokhtari S, Parker P, Karanes C, Palmer J, Snyder D, Forman SJ, Nademanee A, et al. Long-term outcome of allogeneic hematopoietic stem cell transplantation from unrelated donor using tacrolimus/sirolimus-based GVHD prophylaxis: impact of HLA mismatch. Transplantation. 2019.
Salhotra A, Mei M, Stiller T, Mokhtari S, Herrera AF, Chen R, Popplewell L, Zain J, Ali H, Sandhu K, et al. Outcomes of patients with recurrent and refractory lymphoma undergoing allogeneic hematopoietic cell transplantation with BEAM conditioning and sirolimus and tacrolimus based GVHD prophylaxis. Biol Blood Marrow Transplant. 2018.
Bachiashvili K, Francisco L, Chen Y, Bosworth A, Forman SJ, Bhatia R, Bhatia S. Peripheral blood parameter abnormalities precede therapy-related myeloid neoplasms after autologous transplantation for lymphoma. Cancer. 2021.
Mei M, Gupta R, O'Donnell M, Malki MMAl, Aldoss I, Ali H, Farol L, Snyder D, Forman SJ, Nakamura R, et al. Post-allogeneic eculizumab as prophylaxis against hemolysis and thrombosis for patients with hematologic disorders associated with PNH clones. Biol Blood Marrow Transplant. 2019.
Agrawal V, Pourhassan H, Tsai N-C, Ngo D, Koller P, Malki MMAl, Salhotra A, Ali H, Aribi A, Sandhu KS, et al. Post-transplant sinusoidal obstruction syndrome in adult patients with B-cell Acute Lymphoblastic Leukemia treated with pre-transplant Inotuzumab. Transplant Cell Ther. 2023.
Murad JP, Tilakawardane D, Park AK, Lopez LS, Young C, Gibson J, Yamaguchi Y, Lee HJun, Kennewick KT, Gittins BJ, et al. Pre-conditioning Modifies the Tumor Microenvironment to Enhance Solid Tumor CAR T Cell Efficacy and Endogenous Protective Immunity. Mol Ther. 2021.
Giri S, Chen Y, Wu J, Hageman L, Richman J, Francisco L, Landier W, Costa L, McDonald A, Murdaugh D, et al. Reduction in late mortality among patients with Multiple Myeloma treated with Autologous Peripheral Blood Stem Cell Transplantation - a BMTSS Report. Transplant Cell Ther. 2021.
Pourhassan H, La Rosa C, Chiuppesi F, Puing A, Aldoss I, Park Y, Zhou Q, Karpinski V, Faircloth K, Kaltcheva T, et al. Successful outcome of pre-engraftment COVID-19 in an HCT patient: impact of targeted therapies and cellular immunity. Blood Adv. 2022.
Mardiros A, Forman SJ, Budde LE. T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia. Curr Opin Hematol. 2015;22(6):484-488.
Mardiros A, Santos CDos, McDonald T, Brown CE, Wang X, L Budde E, Hoffman L, Aguilar B, Chang W-C, Bretzlaff W, et al. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and anti-tumor effects against human acute myeloid leukemia. Blood. 2013.
Jabbour EJ, Gökbuget N, Kantarjian HM, Thomas X, Larson RA, Yoon S-S, Ghobadi A, Topp MS, Tran Q, Franklin JL, et al. Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study. Cancer. 2019.
Ciurea SO, Malki MMAl, Kongtim P, Zou J, Aung FM, Rondon G, Chen J, Taniguchi M, Otoukesh S, Nademanee A, et al. Treatment of Allosensitized Patients Receiving Allogeneic Transplantation. Blood Adv. 2021.